Solifenacin Succinate With Tamsulosin HCl in Males With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction

ClinicalTrials.gov ID: NCT00507455

Public ClinicalTrials.gov record NCT00507455. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multi-Center Study to Evaluate the Safety of the Co-administration of Solifenacin Succinate With 0.4 mg Tamsulosin Hydrochloride OCAS (TOCAS) Using Urodynamics in Male Subjects With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A study to evaluate the safety of the co-administration of solifenacin succinate with tamsulosin hydrochloride in men with lower urinary tract symptoms (LUTS) and bladder outlet obstruction (BOO).

Study identification

NCT ID: NCT00507455
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Astellas Pharma Inc; Industry
Enrollment: 222 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 45 Years and older
Sex: Male
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 2007 (Type not available)
Primary completion: Aug 2008 (Actual)
Completion: Aug 2008 (Actual)
Last update posted: Aug 6, 2014

2007 – 2008

United States locations

U.S. sites: 17
U.S. states: 12
U.S. cities: 17

Facility	City	State	ZIP	Site status
Not listed	Homewood	Alabama	35209	—
Not listed	La Mesa	California	91942	—
Not listed	Long Beach	California	90806	—
Not listed	San Bernardino	California	92404	—
Not listed	San Diego	California	92108	—
Not listed	Middlebury	Connecticut	06762	—
Not listed	New Port Richey	Florida	34655	—
Not listed	Coeur d'Alene	Idaho	83814	—
Not listed	Des Moines	Iowa	50309	—
Not listed	Iowa City	Iowa	52242	—
Not listed	Watertown	Massachusetts	02472	—
Not listed	Las Vegas	Nevada	89148	—
Not listed	New York	New York	10021	—
Not listed	Greensboro	North Carolina	27403	—
Not listed	Austin	Texas	78705	—
Not listed	San Antonio	Texas	78229	—
Not listed	Charlottesville	Virginia	22908	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00507455, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 6, 2014 · Synced Oct 21, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00507455 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →